ATE364044T1 - 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit - Google Patents
5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeitInfo
- Publication number
- ATE364044T1 ATE364044T1 AT04740057T AT04740057T ATE364044T1 AT E364044 T1 ATE364044 T1 AT E364044T1 AT 04740057 T AT04740057 T AT 04740057T AT 04740057 T AT04740057 T AT 04740057T AT E364044 T1 ATE364044 T1 AT E364044T1
- Authority
- AT
- Austria
- Prior art keywords
- obesity
- treatment
- diabetes
- receptor agonists
- sup
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000004885 piperazines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0314967.1A GB0314967D0 (en) | 2003-06-26 | 2003-06-26 | Piperazine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE364044T1 true ATE364044T1 (de) | 2007-06-15 |
Family
ID=27637436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04740057T ATE364044T1 (de) | 2003-06-26 | 2004-06-18 | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7208494B2 (de) |
| EP (1) | EP1641796B1 (de) |
| JP (1) | JP4362511B2 (de) |
| KR (1) | KR100756113B1 (de) |
| CN (1) | CN100400538C (de) |
| AT (1) | ATE364044T1 (de) |
| AU (1) | AU2004251847B2 (de) |
| BR (1) | BRPI0411936A (de) |
| CA (1) | CA2530308C (de) |
| DE (1) | DE602004006869T2 (de) |
| ES (1) | ES2287741T3 (de) |
| GB (1) | GB0314967D0 (de) |
| MX (1) | MXPA05013856A (de) |
| WO (1) | WO2005000849A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5173190B2 (ja) | 2004-08-25 | 2013-03-27 | 武田薬品工業株式会社 | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
| CN101171252B (zh) * | 2005-05-03 | 2011-06-01 | 霍夫曼-拉罗奇有限公司 | 作为5-ht2配体的四环氮杂吡嗪并二氢吲哚类化合物 |
| WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| WO2007025144A1 (en) * | 2005-08-24 | 2007-03-01 | University Of Illinois - Chicago | 5-ht2c receptor agonists as anorectic agents |
| AU2006314649A1 (en) * | 2005-11-18 | 2007-05-24 | F. Hoffmann-La Roche Ag | Azaindole-2-carboxamide derivatives |
| DE602006010433D1 (de) | 2005-12-09 | 2009-12-24 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
| EP2727585A1 (de) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo Screening-Methode |
| WO2008003641A1 (en) * | 2006-07-04 | 2008-01-10 | Bracco Imaging S.P.A. | Device for localized thermal ablation of biological tissue, particularly tumoral tissues or the like |
| EP2789338A3 (de) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Kondensiertes Pyridinderivat und seine Verwendung |
| EP2348857B1 (de) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Neue cyclische benzimidazolderivate als antidiabetika |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| EP2510949A4 (de) | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | Therapeutikum für fibromyalgie |
| CA2788416C (en) | 2010-02-04 | 2018-08-14 | The Board Of Trustees Of The University Of Illinois | Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN107810175B (zh) | 2015-01-29 | 2021-06-15 | 伊利诺伊大学评议会 | 作为选择性5-ht(2c)受体激动剂的环丙基甲胺 |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| CN118574832A (zh) * | 2022-01-19 | 2024-08-30 | 上海奕拓医药科技有限责任公司 | 三并环化合物、其制备、药物组合物及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3317524A (en) | 1965-02-04 | 1967-05-02 | American Home Prod | Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| US4844839A (en) | 1984-09-04 | 1989-07-04 | Manchak Frank | In situ treatment and analysis of wastes |
| US4776409A (en) | 1984-09-04 | 1988-10-11 | Manchak Frank | Insitu waste impoundment treating apparatus and method of using same |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| US5246960A (en) | 1984-12-21 | 1993-09-21 | Hoffmann-La Roche Inc. | Oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| JPS63500677A (ja) | 1985-08-26 | 1988-03-10 | マンチャック フランク ジュニア | 危険廃棄物現場処理装置およびその使用方法 |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| BR9406128A (pt) | 1993-03-01 | 1996-02-27 | Merck Sharp & Dohme | Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica |
| TW270114B (de) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
| TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
| WO1998030548A1 (en) | 1997-01-13 | 1998-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | 5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| WO2000009123A1 (en) | 1998-08-14 | 2000-02-24 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors and chitosan |
| TR200100471T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri içeren farmasötik bileşimler |
| GB9819032D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds IV |
| GB9819020D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds III |
| GB9819019D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9819033D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
| GB9819035D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
| GB9820767D0 (en) | 1998-09-23 | 1998-11-18 | Cerebrus Ltd | Chemical compounds VIII |
| NZ512765A (en) | 1998-12-17 | 2003-10-31 | Wyeth Corp | 2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)quinoxalin- 5(6H)one derivatives being 5HT2C agonists |
| GB9902047D0 (en) * | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
| GB9918962D0 (en) | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxii |
| GB9918965D0 (en) | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxi |
| EP1132389A1 (de) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit |
| US6635598B2 (en) * | 2000-04-20 | 2003-10-21 | Indian Petrochemicals Corporation Limited | Stable and selective dehydrogenation catalyst and a process for the preparation thereof |
| JP4180365B2 (ja) | 2000-07-31 | 2008-11-12 | エフ．ホフマン−ラ ロシュ アーゲー | ピペラジン誘導体 |
| KR100539143B1 (ko) | 2000-12-27 | 2005-12-26 | 에프. 호프만-라 로슈 아게 | 인돌 유도체 및 그의 5-ｈｔ2ｂ 및 5-ｈｔ2ｃ 수용체리간드로서의 용도 |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
-
2003
- 2003-06-26 GB GBGB0314967.1A patent/GB0314967D0/en not_active Ceased
-
2004
- 2004-06-18 CN CNB2004800179181A patent/CN100400538C/zh not_active Expired - Fee Related
- 2004-06-18 AU AU2004251847A patent/AU2004251847B2/en not_active Ceased
- 2004-06-18 JP JP2006515997A patent/JP4362511B2/ja not_active Expired - Fee Related
- 2004-06-18 ES ES04740057T patent/ES2287741T3/es not_active Expired - Lifetime
- 2004-06-18 DE DE602004006869T patent/DE602004006869T2/de not_active Expired - Lifetime
- 2004-06-18 KR KR1020057024843A patent/KR100756113B1/ko not_active Expired - Fee Related
- 2004-06-18 EP EP04740057A patent/EP1641796B1/de not_active Expired - Lifetime
- 2004-06-18 BR BRPI0411936-3A patent/BRPI0411936A/pt not_active IP Right Cessation
- 2004-06-18 AT AT04740057T patent/ATE364044T1/de not_active IP Right Cessation
- 2004-06-18 WO PCT/EP2004/006612 patent/WO2005000849A1/en not_active Ceased
- 2004-06-18 CA CA002530308A patent/CA2530308C/en not_active Expired - Fee Related
- 2004-06-18 MX MXPA05013856A patent/MXPA05013856A/es unknown
- 2004-06-25 US US10/876,954 patent/US7208494B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060028773A (ko) | 2006-04-03 |
| ES2287741T3 (es) | 2007-12-16 |
| DE602004006869D1 (de) | 2007-07-19 |
| GB0314967D0 (en) | 2003-07-30 |
| AU2004251847A1 (en) | 2005-01-06 |
| DE602004006869T2 (de) | 2008-02-07 |
| CA2530308A1 (en) | 2005-01-06 |
| EP1641796A1 (de) | 2006-04-05 |
| MXPA05013856A (es) | 2006-02-28 |
| US20050026925A1 (en) | 2005-02-03 |
| EP1641796B1 (de) | 2007-06-06 |
| JP4362511B2 (ja) | 2009-11-11 |
| US7208494B2 (en) | 2007-04-24 |
| KR100756113B1 (ko) | 2007-09-05 |
| CA2530308C (en) | 2009-06-09 |
| WO2005000849A1 (en) | 2005-01-06 |
| CN100400538C (zh) | 2008-07-09 |
| JP2007506667A (ja) | 2007-03-22 |
| CN1812989A (zh) | 2006-08-02 |
| AU2004251847B2 (en) | 2007-08-23 |
| BRPI0411936A (pt) | 2006-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE364044T1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
| ATE327977T1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
| SE0202463D0 (sv) | Novel compounds | |
| BR0311541A (pt) | indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas | |
| TNSN04136A1 (en) | Aza-arylpiperazines | |
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| JO2282B1 (en) | Oxazole derivatives | |
| SE0403006D0 (sv) | New compounds | |
| UY26291A1 (es) | Compuestos químicos xxii | |
| MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
| MX2007003546A (es) | Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| DE602004011394D1 (en) | Thiazolderivate | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| EA200601802A1 (ru) | Производные морфолина | |
| TW200508207A (en) | New benzimidazole derivatives | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| SE0403171D0 (sv) | New compounds | |
| MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
| MX2007011695A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
| BRPI0417858A (pt) | composto, composição farmacêutica, e, uso de uma composição farmacêutica | |
| SE0302756D0 (sv) | Novel Compounds | |
| ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| SE0401763D0 (sv) | Compounds | |
| MX2007011698A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1641796 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |